MCK Stock Overview
Provides healthcare services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
McKesson Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$623.19 |
| 52 Week High | US$637.51 |
| 52 Week Low | US$431.35 |
| Beta | 0.44 |
| 11 Month Change | 24.20% |
| 3 Month Change | 12.87% |
| 1 Year Change | 35.07% |
| 33 Year Change | 181.21% |
| 5 Year Change | 330.86% |
| Change since IPO | 3,676.91% |
Recent News & Updates
McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture
Nov 14
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Nov 09Recent updates
McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture
Nov 14McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Nov 09McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Oct 09McKesson: The Correction Is Not Over
Sep 10McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing
Aug 22McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Shareholder Returns
| MCK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.8% | 1.6% | 2.2% |
| 1Y | 35.1% | 2.1% | 31.7% |
Return vs Industry: MCK exceeded the US Healthcare industry which returned 2.1% over the past year.
Return vs Market: MCK exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 5.2% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MCK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MCK's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
McKesson Corporation Fundamentals Summary
| MCK fundamental statistics | |
|---|---|
| Market cap | US$79.75b |
| Earnings (TTM) | US$2.54b |
| Revenue (TTM) | US$330.19b |
31.2x
P/E Ratio0.2x
P/S RatioIs MCK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCK income statement (TTM) | |
|---|---|
| Revenue | US$330.19b |
| Cost of Revenue | US$317.29b |
| Gross Profit | US$12.89b |
| Other Expenses | US$10.36b |
| Earnings | US$2.54b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 19.98 |
| Gross Margin | 3.90% |
| Net Profit Margin | 0.77% |
| Debt/Equity Ratio | -208.9% |
How did MCK perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield13%
Payout RatioDoes MCK pay a reliable dividends?
See MCK dividend history and benchmarks| McKesson dividend dates | |
|---|---|
| Ex Dividend Date | Dec 02 2024 |
| Dividend Pay Date | Jan 02 2025 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 40 days |
Does MCK pay a reliable dividends?
See MCK dividend history and benchmarks